Eric Singhi/faculty.mdanderson.org
May 25, 2025, 17:02
Eric Singhi: Phase 3 HERTHENA-Lung02 Study
Eric Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a post on X:
“Phase 3 HERTHENA-Lung02 study:
-
HER3-DXd v chemo in EGFRm NSCLC post 3G TKI
-
mPFS: 5.8 v 5.4 mo (HR 0.77)
-
ORR: 35% v 25%
-
PFS: 5.4 v 4.2 mo (HR 0.75)
-
TEAEs G≥3: 73% v 57%, mostly thrombocytopenia
-
5% ILD (with 2 G5 events).”
More posts featuring Eric Singhi.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 15, 2025, 16:56
Jun 15, 2025, 16:47
Jun 15, 2025, 16:38
Jun 15, 2025, 15:57
Jun 15, 2025, 15:39